While ZEB1 was verified in CRC cells to inhibit transcription of ubiquitin-specific peptidase 17 (USP17), chromodomain helicase DNA-binding protein 1-like (CHD1L), and double homeobox 4 (DUX4), knockdown of ZEB1 improved CRC cell response to cisplatin (109). Here, DUX4 is linked to colorectal carcinoma.